Accelerate Diagnostics, Inc.

Good day and welcome to Celery Diagnostic Second Quarter 2022 Earnings Call. All participants will be in listen-only mode. If you need assistance, please signal a conference specialist by pressing the star key followed by zero. Please note that this event is being recorded. I'd like to turn the call over to Ms. Laura Pearson. Please go ahead.

Before we begin, it is important to share that information presented during this call may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include projections, statements about our future, and those that are not historical facts. All forward-looking statements that are made during this conference call are subject to risk, uncertainties, and other factors that could cause our actual results to differ materially. These are discussed in greater detail in our annual report on Form 10-K for the year ended December 31st, 2021, and other reports we file with the SEC. It is my pleasure to now introduce the company's president and CEO, Jack Phillips.

Thank you, Laura. Good afternoon, everyone, and welcome to our second quarter earnings call. On today's call, we will discuss our exciting new partnership with Becton Dickinson, our second quarter financial results, and other consequential developments from the quarter, of which there are many. This morning, we announced an exclusive global commercial partnership with Becton Dickinson. The combination of BD's leadership position in microbiology and our innovative products will deliver immediate commercial synergy and strategic value to both companies. I will detail the terms of this arrangement, our rationale for entering into it, and its many benefits later in my prepared remarks. The second quarter's financial and product development results were consistent with our expectations. In addition to strong revenue growth, We made meaningful progress in product development and took another consequential step to improve our balance sheet. Before providing additional detail on our progress during the quarter, I would like to hand it over to our Chief Financial Officer, Steve Reichling, to review our second quarter financial results. Over to you, Steve.